Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PARD $0.34 0.1299 +61.86%
AGIO $43.66 3.3100 +8.20%
PVCT $0.98 0.0701 +7.70%
GALT $5.22 0.3600 +7.41%
SPPI $7.91 0.4000 +5.33%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $17.00 -1.7700 -9.43%
IMNP $3.74 -0.2099 -5.31%
CRIS $1.59 -0.0650 -3.94%
CERU $4.49 -0.1800 -3.85%
GALE $2.15 -0.0500 -2.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 877 | 878 | 879 | 880 | 881 | 882 | 883 | 884 | 885 | 886 | Next > | Last >>

Dana-Farber Physicians Recognized as 'Top Doctors' in Boston Area

(Dana-Farber) Jan 27, 2011 - Thirty-one Dana-Farber Cancer Institute cancer specialists were recognized by Boston magazine for being among the area's top physicians.
read press release 

American Cancer Society’s John R. Seffrin Named to National Prevention Advisory Group

(ACS) Jan 27, 2011 - The White House has announced its intention to appoint John R. Seffrin, Ph.D., chief executive officer of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN), to the advisory group to the newly created National Prevention, Health Promotion and Public Health Council.
read press release 

Tower Cancer Research Foundation to Host Colorectal Cancer Symposium

(Beverly Hills Chamber of Commerce News) Jan 20, 2011 - Tower Cancer Research Foundation, a nonprofit organization dedicated to cutting edge cancer therapy and research, will host the second in its series of free symposiums on March 8.
read press release 

Generics Companies Weigh In on Biological Drugs

(Wall Street Journal) Jan 31, 2011 - Generic drug makers are expecting copies of complex biological drugs to become a multibillion dollar market in the near future. But a lack of clear regulation, intense scrutiny from makers of the original drugs and the high cost of research may damp their prospects.
read article (paid subscription required) 

Sanofi and Genzyme Agree on Structure of a Deal

(NYT DealBook) Jan 31, 2011 - Sanofi-Aventis and Genzyme have reached an agreement in principle on the broad contours of a deal, which will include additional payments to Genzyme shareholders if one of the company’s drugs proves lucrative, people briefed on the matter told DealBook on Monday.
read article (free registration required) 

Pfizer Ordered To Pay $142 Million Over Neurontin Marketing

(Dow Jones Newswires/Morningstar) Jan 28, 2011 - A federal judge in Boston has affirmed a jury award against Pfizer Inc. for violating a U.S. anti-racketeering law by promoting the epilepsy drug Neurontin for unapproved uses such as migraines, and ordered the company to pay $142.1 million in damages, Bloomberg News reported Friday.
read article 

NPS Pharmaceuticals Drug for Rare Bowel Condition Meets Goals in Testing

(Bloomberg) Jan 31, 2011 - NPS Pharmaceuticals Inc. said its experimental therapy, Gattex, helped restore normal intestinal function in patients with a rare bowel condition in a study, clearing the way to apply for regulatory approval.
read article 

Pfizer Hires Glaxo Executive as Senior VP

(CNBC) Jan 31, 2011 - Pfizer Inc., the world's largest drugmaker, named Dr. Yvonne Greenstreet on Monday as the senior vice president and head of medicine development for the specialty care business unit, effective Tuesday.
read article 

Roche's Tarceva Extends Time to Disease Progession in Lung Cancer Study

(Bloomberg) Jan 28, 2011 - Roche Holding AG’s Tarceva medicine extended the time patients with a certain kind of newly diagnosed lung cancer lived without their disease getting worse in a late-stage study.
read article 

New Test Discovered to Better Predict Breast Cancer Outcomes

(McGill University) Jan 27, 2011 - Gene expression signature identified that can accurately assess which patients are at risk of relapse.
read press release 

Obama Suggests US Should Be Able To Negotiate Drug Prices

(Dow Jones Newswires/Morningstar) Jan 27, 2011 - President Barack Obama on Thursday said prescription drug costs should be lower, and suggested giving the government power to directly negotiate drug prices and allowing medicines to be imported from abroad would be ways to lower prices.
read article 

FDA Approves Rituxan for First-Line Maintenance Use in Follicular Lymphoma

(Genentech) Jan 28, 2011 – Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration (FDA) approved Rituxan (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy (induction treatment).
read press release 

Sanofi's Breast Cancer Drug Fails in Advanced Trial of Aggressive Tumors

(Bloomberg) Jan 28, 2011 - Sanofi-Aventis SA, the French drugmaker trying to take over Genzyme Corp. of the U.S., fell the most in six months after saying one of its most promising experimental drugs failed in a key study in breast cancer.
read article 

Novel Surgery Removes Tumor, Rebuilds Trachea

(Henry Ford Health System) Jan 28, 2011 - Using a novel surgical approach, it's possible to rebuild the trachea and preserve a patient's voice after removing an invasive throat tumor, according to a new report from Henry Ford Hospital in Detroit.
read press release 

Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration

(StreetInsider) Jan 28, 2011 - Endo Pharmaceuticals announced today that it has entered into a collaboration agreement with European-based Orion Corporation for the discovery, development and commercialization of assets in Oncology.
read article 

Voice-Saver: Light Therapy for Laryngeal Cancer

(Henry Ford Health System) Jan 28, 2011 - Light, or photodynamic, therapy can help preserve the voice and vocal cord function for patients with early stage laryngeal (voice box) cancer, according to a study from Henry Ford Hospital in Detroit.
read press release 

Myriad Genetics Falls After Sanofi Setback Dims Prospects for Drug Testing

(Bloomberg) Jan 28, 2011 - Myriad Genetics Inc., maker of a test to determine whether breast cancer patients can benefit from an experimental group of medicines, fell the most since May after the leading drug in that class failed in a study.
read article 

H3 Biomedicine Launches to Discover and Develop Next Generation Cancer Treatments Company to Leverage Cancer Genome and Innovative Chemistry

(CNBC) Jan 27, 2010 - H3 Biomedicine Inc. today announced that it has launched research and development operations in Cambridge, Massachusetts.
read article 

Actelion, Glaxo Stop Development of Insomnia Medicine

(Bloomberg/Washington Post) Jan 28, 2011 - Actelion Ltd. and partner GlaxoSmithKline Plc stopped late-stage development of the experimental almorexant insomnia pill because of concern that patients wouldn’t be able to tolerate the medicine.
read article (free registration required) 

Roche's Tarceva Helps Patients in Lung Cancer Type

(Reuters) Jan 28, 2011 - Roche Holding's cancer drug Tarceva allows patients with a certain type of lung cancer to live longer without their disease getting worse, giving the Swiss drugmaker another small boost.
read article 

Cancer Drug Aids the Regeneration of Spinal Cord Injuries

(Max Planck Institute) Jan 28, 2011 - Taxol, the trade name of a drug currently used for cancer treatment, has now been shown to promote regeneration of injured CNS-nerve cells.
read press release 

Biotech Stock Mailbag: Orexigen Therapeutics

(TheStreet) Jan 28, 2011 - Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks, including Cel-Sci and ARIAD.
read article 

Arena Pharmaceuticals Needs A New Boss

(Forbes The Medicine Show Blog) Jan 28, 2011 - San Diego’s Arena Pharmaceuticals, the developer of the experimental weight loss drug lorcaserin, announced last night it will lay off a quarter of its workforce, or 66 employees.
read article 

Protein Related to Aging Holds Breast Cancer Clues

(VUMC Reporter) Jan 27, 2011 - The most common type of breast cancer in older women — estrogen and progesterone receptor (ER/PR) positive breast cancer — has been linked to a protein that fends off aging-related cellular damage.
read press release 

Where Immunotherapy’s Core Science Discovered, Ground-Breaking Cancer Treatment Begins

(Stanford Hospital & Clinics) Jan 27, 2011 - After Peter Alfke stopped responding to regular treatment for prostate cancer, his Stanford Cancer Center physicians, including Russell Pachynski, MD, offered him a ground-breaking immunotherapy treatment that ordered his immune system to recognize his cancer as an enemy.
read press release